Core Viewpoint - The company, Yingjixin Technology Co., Ltd., is actively involved in the development and sales of power management and fast charging protocol chips, with a focus on automotive electronics and consumer electronics sectors. Group 1: Company Overview - Yingjixin was established on November 20, 2014, and went public on April 19, 2022, with its headquarters located in Zhuhai, Guangdong Province [7] - The company's main business revenue composition includes power management (65.15%), mixed-signal SoC (22.02%), battery management (12.33%), and others (0.49%) [7] - As of September 30, 2025, the company had 15,600 shareholders, an increase of 13.58% from the previous period [8] Group 2: Financial Performance - For the period from January to September 2025, Yingjixin achieved operating revenue of 1.169 billion yuan, representing a year-on-year growth of 14.16% [8] - The net profit attributable to the parent company for the same period was 114 million yuan, reflecting a year-on-year increase of 28.54% [8] - The company has distributed a total of 171 million yuan in dividends since its A-share listing, with 155 million yuan distributed over the past three years [9] Group 3: Product Development and Market Position - The company has successfully developed automotive-grade charging chips that meet AEC-Q100 standards and has begun mass production for domestic and international automotive manufacturers [2] - Yingjixin's TWS earphone charging case chip offers a highly integrated power solution, supporting deep customization of MCU software, which reduces design complexity and material costs for customers [2] - The company has established itself as a major supplier of power management and fast charging protocol chips in the consumer electronics market, leveraging its advantages in mobile power and fast charging adapters [2] Group 4: Industry Recognition - Yingjixin has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title awarded to companies that excel in niche markets, possess strong innovation capabilities, and maintain high market share [3]

Group 1 - The core viewpoint of the news is that Yingjixin's stock has experienced fluctuations, with a recent decline in share price and significant trading activity, indicating market volatility [1] - As of January 14, Yingjixin's stock price was 21.38 yuan per share, with a market capitalization of 9.274 billion yuan and a trading volume of 214 million yuan [1] - The company has seen a year-to-date stock price increase of 7.22%, but has declined by 4.89% in the last five trading days [1] Group 2 - Yingjixin reported a revenue of 1.169 billion yuan for the period from January to September 2025, representing a year-on-year growth of 14.16% [2] - The net profit attributable to shareholders for the same period was 114 million yuan, showing a year-on-year increase of 28.54% [2] - The company has distributed a total of 171 million yuan in dividends since its A-share listing, with 155 million yuan distributed over the past three years [3] Group 3 - As of September 30, 2025, Yingjixin had 15,600 shareholders, an increase of 13.58% from the previous period [2] - The average number of circulating shares per shareholder decreased by 11.95% to 19,194 shares [2] - Hong Kong Central Clearing Limited is the seventh largest circulating shareholder, holding 3.3207 million shares, an increase of 614,100 shares from the previous period [3]

中国经济网北京1月13日讯 英集芯(688209.SH)今日股价下跌，收报21.83元，跌幅3.36%。 英集芯于2022年4月19日在上交所科创板上市，发行新股数量为4200.00万股，发行价格为24.23 元/股，保荐机构（主承销商）为华泰联合证券有限责任公司，保荐代表人为张鹏、田来。该股目前处 于破发状态。 英集芯首次公开发行股票的发行费用（不含税）总额为11026.50万元，其中，承销及保荐费用 9070.04万元。 (责任编辑：徐自立) 英集芯首次公开发行股票募集资金总额为10.18亿元，募集资金净额为9.07亿元。英集芯实际募资 净额比原拟募资多5.07亿元。英集芯于2022年4月14日披露的招股说明书显示，该公司原拟募集资金 4.01亿元，分别用于电源管理芯片开发和产业化项目、快充芯片开发和产业化项目、补充流动资金项 目。 ...

Core Viewpoint - The stock price of Yingjixin has shown a positive trend, with a year-to-date increase of 13.19% and a recent uptick in trading activity, indicating potential investor interest and market confidence in the company's growth prospects [2]. Group 1: Stock Performance - As of January 12, Yingjixin's stock rose by 2.13%, reaching a price of 22.57 CNY per share, with a trading volume of 139 million CNY and a turnover rate of 1.44%, resulting in a total market capitalization of 9.791 billion CNY [1]. - The stock has experienced a 5.17% increase over the last five trading days and a 1.85% increase over the last 20 days, while it has seen a decline of 5.88% over the past 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Yingjixin reported a revenue of 1.169 billion CNY, reflecting a year-on-year growth of 14.16%, and a net profit attributable to shareholders of 114 million CNY, which is a 28.54% increase compared to the previous year [2]. - The company has distributed a total of 171 million CNY in dividends since its A-share listing, with 155 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, Yingjixin had 15,600 shareholders, an increase of 13.58% from the previous period, with an average of 19,194 circulating shares per shareholder, which is a decrease of 11.95% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest, holding 3.3207 million shares, an increase of 614,100 shares from the previous period [3].

（文章来源：证券日报） 证券日报网讯 1月9日，英集芯发布公告称，公司2026年第一次临时股东会审议通过《关于预计2026年 度日常关联交易的议案》等。 ...

证券代码：688209 证券简称：英集芯 公告编号：2026-003 深圳英集芯科技股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 1 月 9 日 （二） 股东会召开的地点：广东省珠海市香洲区唐家湾镇港湾一号港 7 栋 3 层 公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 103 | | --- | --- | | 普通股股东人数 | 103 | | 2、出席会议的股东所持有的表决权数量 | 168,248,148 | | 普通股股东所持有表决权数量 | 168,248,148 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 39.1627 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 39.1627 ...

致：深圳英集芯科技股份有限公司 北京市康达律师事务所（以下简称"本所"）接受深圳英集芯科技股份有限公 司（以下简称"公司"）的委托，指派本所律师参加公司 2026 年第一次临时股东 会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《上海证券交易所科创板上市公司自律监管指引第 1 号—— 规范运作》《深圳英集芯科技股份有限公司章程》（以下简称"《公司章程》"）等 规定，就本次会议的召集和召开程序、召集人和出席人员的资格、表决程序以及 表决结果发表法律意见。 关于本《法律意见书》，本所及本所律师谨作如下声明： 北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/W ...

Core Viewpoint - The recent surge in brain-computer interface (BCI) concept stocks has led to significant price increases for companies like Innovent Medical and Nanjing Panda, while companies like YHLO and InnoChip have announced their involvement in the BCI sector, prompting regulatory scrutiny due to incomplete and inaccurate disclosures [1][3][4]. Company Developments - YHLO signed a strategic cooperation framework agreement with Shenzhen Brain Machine Star Chain Technology Co., Ltd., focusing on product development, market promotion, and equity investment [3]. - YHLO specializes in in vitro diagnostic products, primarily using chemiluminescence immunoassay methods for the development, production, and sales of diagnostic instruments and reagents [3]. - InnoChip has entered the BCI chip market with its IPA1299 chip, designed for high-precision measurement of human bioelectric signals, suitable for EEG signal acquisition [3][4]. Market Reactions - Following the announcements, InnoChip's stock price increased by 12.74% from January 5 to 7, while YHLO's stock rose by 6.52% on the day of the announcement, with trading volume up by 299% compared to the previous day [4]. - The Shanghai Stock Exchange raised concerns about the accuracy of the disclosures from both companies, leading to additional disclosures clarifying the status of their BCI-related products [4][5]. Regulatory Actions - The Shanghai Stock Exchange issued regulatory warnings to YHLO and InnoChip for their inaccurate and incomplete information disclosures regarding their BCI initiatives [5][6]. - YHLO clarified that its partner, Brain Machine Star Chain, is focused on non-invasive technology and that its EEG analysis products are still in early development stages [4][6]. Financial Performance - YHLO reported a revenue of approximately 1.287 billion yuan for the first three quarters of 2025, a decrease of 7.69% year-on-year, with a net profit of about 60.42 million yuan, down 72.36% [6]. - In contrast, InnoChip experienced growth in both revenue and net profit, with a net profit of approximately 114 million yuan, an increase of 28.54% year-on-year [6].

Core Viewpoint - The company, Yingjixin Technology Co., Ltd., is experiencing fluctuations in stock performance and is recognized for its advancements in automotive and consumer electronics chip solutions. Group 1: Company Performance - On January 8, Yingjixin's stock fell by 1.69%, with a trading volume of 339 million yuan and a market capitalization of 9.587 billion yuan [1] - As of September 30, the company reported a revenue of 1.169 billion yuan for the first nine months of 2025, representing a year-on-year growth of 14.16%, and a net profit attributable to shareholders of 114 million yuan, up 28.54% year-on-year [8] Group 2: Product Development - The company has successfully developed automotive-grade charging chips that meet AEC-Q100 standards, which have been adopted by domestic and international automotive manufacturers and are now in mass production [2] - Yingjixin's TWS earphone charging case chips provide a highly integrated power solution, supporting deep customization of MCU software, which reduces design complexity and material costs for customers [2] - The company is a major supplier of power management and fast charging protocol chips in the consumer electronics market, leveraging its advantages in mobile power and fast charging adapters [2] Group 3: Industry Recognition - Yingjixin has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in the evaluation of small and medium-sized enterprises in China, indicating its strong market position and innovation capabilities [3] Group 4: Shareholder and Market Activity - As of September 30, the number of shareholders increased to 15,600, a rise of 13.58%, while the average circulating shares per person decreased by 11.95% [8] - The company has distributed a total of 171 million yuan in dividends since its A-share listing, with 155 million yuan distributed over the past three years [9]

Core Viewpoint - The "brain-computer interface" has become a market hotspot, leading to significant stock price increases for several companies, which has drawn regulatory scrutiny [1][2]. Group 1: Regulatory Actions - On January 7, the Shanghai Stock Exchange issued regulatory warnings to companies including Yahui Long and Yingjixin for inaccurate and incomplete disclosures related to their "brain-computer interface" business [1][2]. - Yahui Long's stock price rose by 6.52% on January 6, with trading volume increasing by 299% compared to the previous trading day [2]. - Yingjixin's response to investor inquiries about its IPA1299 chip, which is designed for high-precision measurement of biological electrical signals, led to regulatory scrutiny due to misleading implications about its market readiness and performance [2][3]. Group 2: Company Disclosures - Yahui Long disclosed a strategic cooperation agreement with Shenzhen Brain Machine Star Chain Technology Co., stating that the latter is a leading company in both non-invasive and invasive technology paths, which prompted regulatory inquiries [1]. - Following regulatory pressure, Yahui Long clarified that Brain Machine Star Chain is currently focused on non-invasive technology and that its products are still in early research and development stages [1][3]. - Yingjixin's IPA1299 chip is a joint product with a subsidiary and is still in the market cultivation phase, with no significant impact on the company's performance yet [3]. Group 3: Market Reactions - Several companies, including Weisi Medical, Xiangyu Medical, and Mailande, experienced significant stock price increases, with cumulative price deviations exceeding 30% over two consecutive trading days, triggering abnormal trading notifications [3][4]. - Despite their involvement in the brain-computer interface sector, these companies primarily focus on rehabilitation medical devices, and their related business activities are still in the research or early exploration stages, not significantly impacting their operational performance in the short term [4].